AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic  for post-operative pain AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine  AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund… Continue reading AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

Silicon Labs Reports Third Quarter 2025 Results

Wireless IoT leader delivers sequential and year-over-year growth in sales and profitability AUSTIN, Texas, Nov. 4, 2025 /PRNewswire/ — Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the third quarter, which ended October 4, 2025. “The Silicon Labs team delivered sequential and year-over-year growth in sales and profitability driven by strong… Continue reading Silicon Labs Reports Third Quarter 2025 Results

LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction

BEIJING, Nov. 4, 2025 /PRNewswire/ — LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into an Agreement and Plan of Merger… Continue reading LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy, securing a total of $225 million in non-dilutive capital year-to-date 2025 GAITHERSBURG, Md., Nov. 4, 2025 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of… Continue reading Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Heartland Forward Launches First-Ever Heartland AI Caucus

The bipartisan group of state legislators and executive officers will focus on developing responsible AI policies while advancing AI-powered economic growth opportunities across the heartland OKLAHOMA CITY, Nov. 4, 2025 /PRNewswire/ — Today, Heartland Forward announced the launch of the Heartland AI Caucus, a bipartisan group of state leaders committed to creating and accelerating smart AI… Continue reading Heartland Forward Launches First-Ever Heartland AI Caucus

@Ferrari: CONSISTENT EXECUTION: STRONG Q3 2025 RESULTS000449

Net revenues of Euro 1,766 million, up 7.4% versus prior year, with total shipments of 3,401 units Operating profit (EBIT)(1) of Euro 503 million, up 7.6% versus prior year, with Operating profit (EBIT) margin of 28.4% Net profit of Euro 382 million and diluted EPS at Euro 2.14 EBITDA(1) of Euro 670 million, up 5.0%… Continue reading @Ferrari: CONSISTENT EXECUTION: STRONG Q3 2025 RESULTS000449

Party Supplies Market to Reach $28.7 Billion, Globally, by 2031 at 9.0% CAGR: Allied Market Research

The growth of the global party supplies market is driven by the increase in event management and wedding planning business globally, rise in urban population, and product innovations.  WILMINGTON, Del., Nov. 4, 2025 /PRNewswire/ — Allied Market Research published a report, titled, “Party Supplies Market by Product Type (Balloons, Banners, Pinatas, Games, Home Decor, Tableware/Disposables,… Continue reading Party Supplies Market to Reach $28.7 Billion, Globally, by 2031 at 9.0% CAGR: Allied Market Research

EMBRAER EARNINGS RESULTS 3rd QUARTER 2025

SÃO PAULO, Nov. 4, 2025 /PRNewswire/ — EMBRAER S.A. (NYSE: EMBJ; B3: EMBJ3) RELEASES ITS THIRD QUARTER 2025 EARNINGS RESULTS. HIGHLIGHTS 2025 Guidance re-iterated. From an operations point of view, the company estimates Commercial Aviation deliveries between 77and 85 aircraft, and Executive Aviation deliveries between 145 and 155 aircraft. From a financial point of view,… Continue reading EMBRAER EARNINGS RESULTS 3rd QUARTER 2025

Novelis Reports Second Quarter Fiscal Year 2026 Results

Q2 Fiscal Year 2026 Highlights Net income attributable to our common shareholder of $163 million, up 27% YoY; Net income attributable to our common shareholder excluding special items was $113 million, down 37% YoY Adjusted EBITDA of $422 million, down 9% YoY Rolled product shipments of 941 kilotonnes, in line with the prior year period… Continue reading Novelis Reports Second Quarter Fiscal Year 2026 Results

Ascend Releases Cash Application Solution for Brokers

Cash Application helps brokers achieve compliant operations and turn unapplied cash into real revenue SAN FRANCISCO, Nov. 4, 2025 /PRNewswire/ — Ascend, the only complete accounting automation platform for the insurance industry, today announced the launch of Cash Application, a solution designed to help top brokers reduce unapplied cash balances caused by manual accounts receivable workflows.… Continue reading Ascend Releases Cash Application Solution for Brokers